Treeline Biosciences plans to go public by merging with Standard BioTools in an all‑stock reverse merger, with the combined company to trade on Nasdaq under the ticker TRLN in the second half of 2026.
The combined business will operate under the Treeline Biosciences name, retain Treeline’s clinical‑stage oncology pipeline, and have over $900 million in pro‑forma cash, providing a runway into 2029.
Standard BioTools shareholders will own about 16% of the combined company, while Treeline shareholders will hold roughly 84%; Standard is also exploring divestitures of its Mass Cytometry and Microfluidics businesses.
Sources:
Treeline sees path to public markets via reverse merger
Standard BioTools and Treeline Biosciences Announce Merger ...
Invest In Treeline Biosciences Stock | Buy Pre-IPO Shares | EquityZen
Fenwick Represents Treeline Biosciences in Definitive Merger Agreement with Standard BioTools
Standard BioTools Is Merging With Treeline Biosciences - Finimize
Standard BioTools, Treeline Biosciences to Merge in All-Stock ...
Investor Presentation March 2025
Standard BioTools (NASDAQ: LAB) to merge with Treeline in $2.5B exchange‑ratio deal